January 15, 2026 8:16 am

Latest Posts

New Hope for Severe Crohn’s: Breakthrough Drug Targets Scarring

Agomab Therapeutics has launched a groundbreaking clinical trial for ontunisertib, a drug specifically targeting fibrostenosing Crohn’s disease—the severe, scarring form that has limited treatment options. This represents the first targeted therapy designed to address the root cause of intestinal scarring rather than just managing symptoms.

The FMT Study That Didn’t Work: What It Teaches Us About Crohn’s

A recent study tested fecal microbiota transplantation (FMT) for Crohn’s disease with disappointing results—but what can we learn from this setback? While FMT didn’t improve remission rates in 8 weeks, the research offers valuable insights for future treatments and reminds us that progress in IBD research often comes through understanding what doesn’t work.

You Missed

Breakthrough Rapid Test Could Transform IBD Diagnosis: What This Means for Patients

Breakthrough Rapid Test Could Transform IBD Diagnosis: What This Means for Patients

January 13, 2026
Navigating IBD Medication Shortages: Your Emergency Action Plan

Navigating IBD Medication Shortages: Your Emergency Action Plan

January 12, 2026
Total Abdominal Colectomy Shows Promise for Ulcerative Colitis: What This Means for Your Treatment Journey

Total Abdominal Colectomy Shows Promise for Ulcerative Colitis: What This Means for Your Treatment Journey

January 12, 2026
This Week in IBD: Your Weekly Roundup for January 5-11, 2026

This Week in IBD: Your Weekly Roundup for January 5-11, 2026

January 11, 2026